Duncan Stewart
Performing a gene and cell therapy trial for heart attack patients with Duncan Stewart
Cardiopulmonary & Vascular Cell & Gene Therapy Methods & Technologies
Video Journal of Biomedicine | Expert Perspective
In this interview, Duncan Stewart from the Ontario Institute for Regenerative Medicine, Canada, discusses his ongoing ENACT-AMI trial studying angiogenic cell therapy to promote repair after a massive heart attack using endothelial NO-synthase (eNOS)-enhanced endothelial progenitor cells (EPCs). Duncan also shares his thoughts on whether regenerative medicine has lived up to its hype.
Duncan Stewart is a pioneering Canadian cardiovascular researcher who is recognized for his many important discoveries in blood vessel biology, as well as his dedication to translating these discoveries into benefits for patients and society. After beginning his career in academic cardiology at McGill University in Montreal, he moved to Toronto as Head of Cardiology at St. Michael's Hospital and later became Director of the Division of Cardiology and Executive Director of the McLaughlin Centre for Molecular Medicine at the University of Toronto. He was recruited to lead the Ottawa Hospital Research Institute in 2007. Duncan has made a number of seminal discoveries elucidating the importance of endothelial factors in health and disease, notably the role of the nitric oxide system in angiogenesis and of endothelin-1 in pulmonary hypertension. Further information on Duncan's research is available here.
Video originally published on RegMedNet from the Future Science Group, a digital platform that unites the diverse regenerative medicine community.
27 Apr 2020 Obstetrics & Gynecology
Developing a fetal gene therapy with Anna David
11 Nov 2019 Neurology & Psychiatry
A first-in-human, gene-silencing treatment for Alzheimer's disease with Catherine Mummery
26 Jun 2017 Methods & Technologies
Mesenchymal stem cells for cardiac regeneration with Massimiliano Gnecchi
25 Feb 2021 Animated Videos
Plain language summary of the ARAMIS study: Darolutamide and survival in nonmetastatic, castration-resistant prostate cancer